Prilenia Therapeutics

Company Overview

Snapshot

Founded in May 2018, Prilenia Therapeutics operates with 51–200 employees. The company has raised a total of $144.5M across 4 funding rounds from 9 investors. In April 2022, SV Health Investors.

Business overview

Prilenia Therapeutics is a late clinical-stage biotechnology company focused on developing novel therapeutics for neurodegenerative diseases and neurodevelopmental disorders. The company's core product, pridopidine, is a first-in-class, oral, highly selective, and potent investigational S1R agonist. Prilenia is currently advancing pridopidine through pre-registration for Huntington's disease (HD) and Phase 3 development for amyotrophic lateral sclerosis (ALS), serving the pharmaceutical and biotechnology sectors within Health Tech & Life Sciences.

Strategic signal

In January 2024, Prilenia Therapeutics announced clinical data supporting its plans to initiate a global Phase 3 study in ALS. This signals a significant advancement in the company's development pipeline for a critical neurodegenerative disease, indicating strong progress towards potential market entry and validating its therapeutic approach for investors.

Company Intelligence Q&A

What is Prilenia Therapeutics' primary focus?

Prilenia Therapeutics is a late clinical-stage biotechnology company focused on developing novel therapeutics to address the progression of neurodegenerative diseases and neurodevelopmental disorders, with an initial focus on Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS).

What is Prilenia Therapeutics' lead compound?

Prilenia Therapeutics' lead compound is pridopidine, a first-in-class, oral, highly selective, and potent investigational S1R agonist. It is in pre-registration for Huntington's disease and Phase 3 development for ALS.

Which investors participated in Prilenia Therapeutics' Series B funding round in April 2022?

In April 2022, SV Health Investors.

When did Prilenia Therapeutics enroll its first patients in the PROOF-HD Phase 3 clinical trial?

Prilenia Therapeutics enrolled its first patients into the PROOF-HD Phase 3 clinical trial for Huntington's Disease in the United States in October 2020, and in Europe in January 2021.

What regulatory designations has pridopidine received?

Pridopidine has received Orphan Drug designation for Huntington's disease and ALS in the U.S. and EU. Additionally, it has received Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of Huntington's disease.